Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal
Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.
You may also be interested in...
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.